Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Vascular targeting agents as cancer therapeutics.

Thorpe PE.

Clin Cancer Res. 2004 Jan 15;10(2):415-27. Review.

2.

The first international conference on vascular targeting: meeting overview.

Thorpe PE, Chaplin DJ, Blakey DC.

Cancer Res. 2003 Mar 1;63(5):1144-7.

3.

AVE8062: a new combretastatin derivative vascular disrupting agent.

Delmonte A, Sessa C.

Expert Opin Investig Drugs. 2009 Oct;18(10):1541-8. doi: 10.1517/13543780903213697. Review.

PMID:
19758109
4.

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.

Cooney MM, Ortiz J, Bukowski RM, Remick SC.

Curr Oncol Rep. 2005 Mar;7(2):90-5. Review.

PMID:
15717941
5.

Vascular-targeting therapies for treatment of malignant disease.

Siemann DW, Chaplin DJ, Horsman MR.

Cancer. 2004 Jun 15;100(12):2491-9. Review.

6.

Vascular disrupting agents: a new class of drug in cancer therapy.

Gaya AM, Rustin GJ.

Clin Oncol (R Coll Radiol). 2005 Jun;17(4):277-90. Review.

PMID:
15997924
7.

Combination of vascular targeting agents with thermal or radiation therapy.

Horsman MR, Murata R.

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1518-23.

PMID:
12459380
8.

Small molecule vascular disrupting agents: potential new drugs for cancer treatment.

Cai SX.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):79-101. Review.

PMID:
18221055
9.

Current development status of small-molecule vascular disrupting agents.

Chaplin DJ, Horsman MR, Siemann DW.

Curr Opin Investig Drugs. 2006 Jun;7(6):522-8. Review.

PMID:
16784022
10.

Vascular targeting therapy: potential benefit depends on tumor and host related effects.

Horsman MR, Bohn AB, Busk M.

Exp Oncol. 2010 Sep;32(3):143-8. Review.

PMID:
21403608
11.

Vascular targeting agents.

Pilat MJ, McCormick J, LoRusso PM.

Curr Oncol Rep. 2004 Mar;6(2):103-10. Review.

PMID:
14751087
12.

Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?

Raben D, Ryan A.

Clin Lung Cancer. 2005 Nov;7(3):175-9. Review.

PMID:
16354311
13.

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, Cai SR, Arbeit JM, Voest EE, Chaplin DJ, Smythe J, Harris A, Nathan P, Judson I, Rustin G, Bertolini F, Link DC, Kerbel RS.

Cancer Res. 2009 Oct 1;69(19):7524-8. doi: 10.1158/0008-5472.CAN-09-0381. Epub 2009 Sep 8.

14.

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.

Jain RK.

Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9. Review.

PMID:
12516032
15.
16.

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.

Siemann DW, Mercer E, Lepler S, Rojiani AM.

Int J Cancer. 2002 May 1;99(1):1-6.

17.

Vascular disrupting agents.

Lippert JW 3rd.

Bioorg Med Chem. 2007 Jan 15;15(2):605-15. Epub 2006 Oct 27.

PMID:
17070061
18.

Combretastatin A4 phosphate: background and current clinical status.

Young SL, Chaplin DJ.

Expert Opin Investig Drugs. 2004 Sep;13(9):1171-82. Review.

PMID:
15330748
19.
20.

Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126.

Siemann DW, Rojiani AM.

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1512-7.

PMID:
12459379

Supplemental Content

Support Center